Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,486.20 +8.30 (+0.15%) Dow
39,237.78 +109.98 (+0.28%) Nasdaq
17,852.10 +46.95 (+0.26%) Bitcoin USD
61,960.74 +346.20 (+0.56%) CMC Crypto 200
1,295.31 +29.17 (+2.30%)
EDIT240705P00006000
- Insider Monkey
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other small-cap stocks. Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion. They are usually […]
- Zacks
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
- GlobeNewswire
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
